Gilead Sciences, Inc. (GILD)
| Market Cap | 170.94B |
| Revenue (ttm) | 29.09B |
| Net Income (ttm) | 8.11B |
| Shares Out | 1.24B |
| EPS (ttm) | 6.42 |
| PE Ratio | 21.45 |
| Forward PE | 16.29 |
| Dividend | $3.16 (2.29%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 10,012,398 |
| Open | 135.88 |
| Previous Close | 135.93 |
| Day's Range | 133.69 - 138.03 |
| 52-Week Range | 93.10 - 138.03 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 129.10 (-6.3%) |
| Earnings Date | Feb 10, 2026 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $129.1, which is a decrease of -6.30% from the latest price.
News
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEY...
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Li...
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion...
Gilead Sciences: From All-Time Highs To Higher Highs
Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June 18 la...
Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry conference that kicked off on Monday in Sa...
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
Daniel O'Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication...
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate
DALLAS--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”) today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (“Gilead”) to evaluate OncoNano's ON-BOARD™ encapsulati...
Gilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con...
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combine...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company's ...
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective ...
Gilead's experimental HIV treatment meets main goal in late-stage trial
Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial.
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment re...
Gilead, Arcus scrap late-stage trial of cancer drug combo
Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers afte...
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consisten...
Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-ce...
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene aut...
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript